QQQ   359.07 (+0.30%)
AAPL   171.27 (+0.34%)
MSFT   317.05 (+1.09%)
META   303.33 (-0.21%)
GOOGL   131.64 (-0.51%)
AMZN   127.32 (+1.06%)
TSLA   250.94 (+1.85%)
NVDA   436.03 (+1.19%)
NIO   9.04 (+1.46%)
BABA   86.86 (+1.54%)
AMD   103.50 (+0.72%)
T   14.97 (-0.27%)
F   12.49 (-0.56%)
MU   67.76 (+3.93%)
CGC   0.80 (-2.22%)
GE   110.34 (-1.78%)
DIS   80.71 (+0.72%)
AMC   8.10 (+3.98%)
PFE   33.01 (+2.87%)
PYPL   58.40 (+0.38%)
NFLX   376.74 (+0.10%)
QQQ   359.07 (+0.30%)
AAPL   171.27 (+0.34%)
MSFT   317.05 (+1.09%)
META   303.33 (-0.21%)
GOOGL   131.64 (-0.51%)
AMZN   127.32 (+1.06%)
TSLA   250.94 (+1.85%)
NVDA   436.03 (+1.19%)
NIO   9.04 (+1.46%)
BABA   86.86 (+1.54%)
AMD   103.50 (+0.72%)
T   14.97 (-0.27%)
F   12.49 (-0.56%)
MU   67.76 (+3.93%)
CGC   0.80 (-2.22%)
GE   110.34 (-1.78%)
DIS   80.71 (+0.72%)
AMC   8.10 (+3.98%)
PFE   33.01 (+2.87%)
PYPL   58.40 (+0.38%)
NFLX   376.74 (+0.10%)
QQQ   359.07 (+0.30%)
AAPL   171.27 (+0.34%)
MSFT   317.05 (+1.09%)
META   303.33 (-0.21%)
GOOGL   131.64 (-0.51%)
AMZN   127.32 (+1.06%)
TSLA   250.94 (+1.85%)
NVDA   436.03 (+1.19%)
NIO   9.04 (+1.46%)
BABA   86.86 (+1.54%)
AMD   103.50 (+0.72%)
T   14.97 (-0.27%)
F   12.49 (-0.56%)
MU   67.76 (+3.93%)
CGC   0.80 (-2.22%)
GE   110.34 (-1.78%)
DIS   80.71 (+0.72%)
AMC   8.10 (+3.98%)
PFE   33.01 (+2.87%)
PYPL   58.40 (+0.38%)
NFLX   376.74 (+0.10%)
QQQ   359.07 (+0.30%)
AAPL   171.27 (+0.34%)
MSFT   317.05 (+1.09%)
META   303.33 (-0.21%)
GOOGL   131.64 (-0.51%)
AMZN   127.32 (+1.06%)
TSLA   250.94 (+1.85%)
NVDA   436.03 (+1.19%)
NIO   9.04 (+1.46%)
BABA   86.86 (+1.54%)
AMD   103.50 (+0.72%)
T   14.97 (-0.27%)
F   12.49 (-0.56%)
MU   67.76 (+3.93%)
CGC   0.80 (-2.22%)
GE   110.34 (-1.78%)
DIS   80.71 (+0.72%)
AMC   8.10 (+3.98%)
PFE   33.01 (+2.87%)
PYPL   58.40 (+0.38%)
NFLX   376.74 (+0.10%)
NASDAQ:PNT

POINT Biopharma Global (PNT) Stock Forecast, Price & News

$6.67
-0.11 (-1.62%)
(As of 12:56 PM ET)
Compare
Today's Range
$6.65
$6.91
50-Day Range
$6.78
$9.17
52-Week Range
$5.59
$11.13
Volume
112,742 shs
Average Volume
618,051 shs
Market Capitalization
$705.49 million
P/E Ratio
7.67
Dividend Yield
N/A
Price Target
$14.33

POINT Biopharma Global MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
114.9% Upside
$14.33 Price Target
Short Interest
Bearish
8.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.45mentions of POINT Biopharma Global in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.00) to ($0.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

346th out of 971 stocks

Pharmaceutical Preparations Industry

146th out of 451 stocks


PNT stock logo

About POINT Biopharma Global (NASDAQ:PNT) Stock

POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

PNT Price History

PNT Stock News Headlines

This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
Point Biopharma Global (NASDAQ: PNT)
See More Headlines
Receive PNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter.

PNT Company Calendar

Last Earnings
8/14/2023
Today
9/29/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PNT
Fax
N/A
Employees
129
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.33
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+111.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$98.29 million
Pretax Margin
52.79%

Debt

Sales & Book Value

Annual Sales
$226.58 million
Cash Flow
$0.93 per share
Book Value
$4.68 per share

Miscellaneous

Free Float
88,843,000
Market Cap
$717.12 million
Optionable
Not Optionable
Beta
0.13
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Allan Charles Silber (Age 73)
    Exec. Chairman
    Comp: $1.02M
  • Dr. Joe A. McCann Ph.D. (Age 45)
    CEO & Director
    Comp: $1.06M
  • Dr. Neil E. Fleshner FRCSC (Age 59)
    M.D., M.PH, Chief Medical Officer & Director
    Comp: $318.49k
  • Ms. Jessica D. Jensen M.P.H. (Age 42)
    MPH, Exec. VP of Clinical Devel.
    Comp: $816.17k
  • Mr. Bill Demers B.B.A. (Age 64)
    F.C.A., FCPA, CFO & Corp. Sec.
  • Ms. Justyna Kelly M.Sc. (Age 38)
    Chief Operating Officer
  • Ms. Jazz Braich
    SVP of People & Culture
  • Mr. Ari Shomair
    VP of Corp. Affairs & Chief of Staff
  • Dr. Myra Rosario Herle Ph.D.
    R.Ph., Exec. VP of Regulatory Affairs
  • Dr. Matthew P. Vincent J.D.
    Ph.D., Sr. VP of Bus. Devel.













PNT Stock - Frequently Asked Questions

Should I buy or sell POINT Biopharma Global stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PNT shares.
View PNT analyst ratings
or view top-rated stocks.

What is POINT Biopharma Global's stock price forecast for 2023?

5 Wall Street analysts have issued 12-month price targets for POINT Biopharma Global's stock. Their PNT share price forecasts range from $13.00 to $16.00. On average, they anticipate the company's share price to reach $14.33 in the next twelve months. This suggests a possible upside of 111.4% from the stock's current price.
View analysts price targets for PNT
or view top-rated stocks among Wall Street analysts.

How have PNT shares performed in 2023?

POINT Biopharma Global's stock was trading at $7.29 at the start of the year. Since then, PNT stock has decreased by 7.0% and is now trading at $6.78.
View the best growth stocks for 2023 here
.

When is POINT Biopharma Global's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our PNT earnings forecast
.

How were POINT Biopharma Global's earnings last quarter?

POINT Biopharma Global Inc. (NASDAQ:PNT) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.05. The firm earned $4.87 million during the quarter, compared to the consensus estimate of $8.50 million.

What is POINT Biopharma Global's stock symbol?

POINT Biopharma Global trades on the NASDAQ under the ticker symbol "PNT."

How do I buy shares of POINT Biopharma Global?

Shares of PNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is POINT Biopharma Global's stock price today?

One share of PNT stock can currently be purchased for approximately $6.78.

How much money does POINT Biopharma Global make?

POINT Biopharma Global (NASDAQ:PNT) has a market capitalization of $717.12 million and generates $226.58 million in revenue each year. The company earns $98.29 million in net income (profit) each year or $0.87 on an earnings per share basis.

How many employees does POINT Biopharma Global have?

The company employs 129 workers across the globe.

How can I contact POINT Biopharma Global?

POINT Biopharma Global's mailing address is 200 BERKELEY STREET 18TH FLOOR, BOSTON MA, 02116. The official website for the company is www.pointbiopharma.com. The company can be reached via phone at 64-7812-2417.

This page (NASDAQ:PNT) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -